🧠 This Week in Immunology: Light Therapy for Crohn’s, Skin Disease Declared a Priority, and a $9.5B Biotech Acquisition
Stay up to date with the latest developments in immunology—spanning first-in-human trials, public health milestones, and multi-billion dollar immunology expansions:
💡 PhotoPill launches a clinical trial for its IBD-Cap capsule in Crohn’s disease—offering non-invasive, drug-free light therapy for flare-up management.
🌍 The World Health Organization officially declares skin disease a global public health priority—impacting over 2 billion people and calling for urgent action.
💊 Bambusa doses the first patient in its Phase 1 trial for BBT002 and expands U.S. IND clearance for BBT001—targeting multi-organ inflammatory pathways.
✅ NICE recommends mirikizumab for Crohn’s patients unresponsive to biologics—45% achieved remission at one year in Phase 3 trials.
🔬 Enthera publishes data for Ebrasodebart—demonstrating mucosal healing by targeting TMEM219 in ulcerative colitis models.
🧴 LEO Pharma begins a Phase 2a trial for delgocitinib cream in chronic PPP—building on approvals for hand eczema treatment.
💸 Kamari Pharma raises $23M to develop its TRPV3 inhibitor KM023—now entering Phase 1b for rare genetic skin diseases like Olmsted syndrome.
🧬 Recludix and Sanofi progress oral STAT6 inhibitor REX-8756—triggering a $50M milestone, with an IND filing expected in late 2025.
🤝 Sanofi to acquire Blueprint Medicines in a $9.5B deal—adding Ayvakit and two pipeline immunology assets to its growing portfolio.
📢 Stay Ahead in Immunology Research!
✅ Like, share, and subscribe for weekly updates on the latest in immunology and autoimmune diseases
#Immunology #CrohnsDisease #UlcerativeColitis #LightTherapy #SkinHealth #GlobalHealth #Sanofi #BiotechNews #PsoriasisCare #STAT6Inhibitor #ClinicalTrials #LucidQuest #ImmunologyUpdates